AbbVieUS00287Y1091ABBVABBV
Financials
Market Cap
$282.63B5Y beta
0.59EPS (TTM)
$2.719Free Float
1.77BP/E ratio (TTM)
58.70Revenue (TTM)
$54.32BEBITDA (TTM)
$25.41BFree Cashflow (TTM)
$11.52BPricing
Analyst Ratings
The price target is $183.83 and the stock is covered by 27 analysts.
Buy
17
Hold
10
Sell
0
Information
AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care products, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis and Other eye care, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers.